MOSAIQ®

RA: Rheumatoid arthritis

Coming Soon


AiPlex[™] CTDplus Connective Tissue Disease Microarray Solution

Designed to provide comprehensive CTD diagnostic insights and workflow efficiency

Autoimmune connective tissue diseases (CTD) are complex disorders that may present with a wide spectrum of non-specific manifestations and its differential diagnosis remain clinically challenging.¹ These difficulties frequently result in prolonged times between symptoms onset and diagnosis.¹ Evaluation of multiple autoantibodies may assist clinicians in the assessment of these conditions.

Our targeted menu covers 15 markers in one panel.²⁻¹⁰

In development, subject to regulatory authorizations.



Fast, Easy, Comprehensive

Includes most of the key markers recommended by clinical guidelines (ACR and EULAR) ²⁻⁸

As the prevalence of autoimmune rheumatic disorders such as RA will continue to grow,¹¹ the demand for highthroughput testing solutions will increase. Autoantibody panels may also help identify common comorbidities within connective diseases. Results for anti-dsDNA and Anti-CCP are standardized against WHO standards in IU/ml, while other markers are assessed semi-quantitatively.

9	-	٦	2	
	l			
	9			

Generates multiple insights in one report with only 10 µl patient sample. One microarray provides up to 15 individual results.



Saves time while avoiding human errors with a standardized master curve embedded into RFID* tags, included with all reagents and microarrays.

* RFID: Radio Frequency Identification



Reduces hands-on time and storage space with ready to use, concentrated onboard reagents and buffers.



Shares key reagents with other panels, enabling combined autoimmunity, allergy, and further testing.

AiPlex CTDplus, running on the MosaiQ platform, is designed to reduce the time to results for patients with CTD.



Simple Workflow

- Patients sample in, results out in one single step
- QC and calibration embedded



- Results within one day
- One sample tube (low volume) for multiple tests



⁷ van den Hoogen F. Arthritis Rheum. 2013;65(11):2737.
⁸ Aletaha D. Arthritis Rheum. 2010:62(9):2569.

9 Decker P. Eur J Intern Med. 2021;91:45-52

¹⁰ Mahler M. J Immunol Res. 2014;2014:315179.

Actionable Insights

- Panels help streamline clinical decision-making for physicians
- Comprehensive panels simplifly complex testing pathways

- ¹ Kernder A. Rheumatol Int. 2023;43(8):1453.
- ² Aringer M. Ann Rheum Dis. 2019;78:1151.
- ³ Shiboski CH. Arthritis Rheumatol. 2017;69(1):35.
- ⁴ Lundberg IE. Arthritis Rheumatol. 2017;69(12):2271.
- ⁵ Alarcón-Segovia D. J. Rheumatol. 1989;16(3):328.
- ⁶ Tanaka Y. Modern Rheumatology. 2021;31(1):29.



© AliveDx Suisse SA, 2024. The AliveDx logo, AliveDx, AiPlex and MosaiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories. In development subject to regulatory authorization. GFD# 0.0120x1

